From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Definition and Mechanism of Sermorelin
- Sermorelin, a 29 amino acid analogue of human growth hormone-releasing hormone (GHRH), is the shortest synthetic peptide with full biological activity of GHRH 1.
- It specifically stimulates growth hormone secretion from the anterior pituitary, and its effects can be used to diagnose and treat growth hormone deficiency 1, 2.
Uses of Sermorelin
- Sermorelin is used as a provocative test for the diagnosis of growth hormone deficiency, with a rapid and relatively specific response to intravenous administration 1.
- It is also used to treat idiopathic growth hormone deficiency in prepubertal children, with significant increases in height velocity and catch-up growth observed in some patients 1.
- Additionally, sermorelin has been shown to have extrapituitary effects, including stimulation of cell proliferation, survival, and differentiation, and inhibition of apoptosis 3, 4, 5.
Extrapituitary Effects of GHRH
- GHRH has been shown to have a wide range of extrapituitary effects, including regulation of pancreatic islet and β-cell survival and function, endometrial cell proliferation, cardioprotection, and wound healing 3, 4, 5.
- GHRH and its analogs may have potential therapeutic uses in a variety of medical settings, including the treatment of malignancies, regulation of metabolism, and promotion of healing and survival of tissues 3, 4, 5.
Administration and Tolerance
- Sermorelin can be administered intravenously or subcutaneously, with a recommended dosage of 30 microg/kg bodyweight per day for the treatment of idiopathic growth hormone deficiency 1.
- The effects of sermorelin have been shown to be well-tolerated, with transient facial flushing and pain at the injection site being the most commonly reported adverse events 1.